Drug Prevention and Control of Ventilator-Associated Pneumonia
Ventilator-associated pneumonia (VAP) is one of the most prevalent and serious complications of mechanical ventilation, which is considered a common nosocomial infection in critically ill patients. There are some great options for the prevention of VAP: (i) minimize ventilator exposure; (ii) intensi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00298/full |
| _version_ | 1818430783042355200 |
|---|---|
| author | Xinming Xie Jun Lyu Tafseel Hussain Manxiang Li |
| author_facet | Xinming Xie Jun Lyu Tafseel Hussain Manxiang Li |
| author_sort | Xinming Xie |
| collection | DOAJ |
| description | Ventilator-associated pneumonia (VAP) is one of the most prevalent and serious complications of mechanical ventilation, which is considered a common nosocomial infection in critically ill patients. There are some great options for the prevention of VAP: (i) minimize ventilator exposure; (ii) intensive oral care; (iii) aspiration of subglottic secretions; (iv) maintain optimal positioning and encourage mobility; and (v) prophylactic probiotics. Furthermore, clinical management of VAP depends on appropriate antimicrobial therapy, which needs to be selected based on individual patient factors, such as previous antibacterial therapy, history of hospitalization or mechanical ventilation, and bacterial pathogens and antibiotic resistance patterns. In fact, antibiotic resistance has exponentially increased over the last decade, and the isolation of a multidrug-resistant (MDR) pathogen has been identified as an independent predictor of inadequate initial antibiotic therapy and which is significantly associated with increased mortality. Multiple attempts were used in the treatment of VAP, such as novel antibacterial agents, inhaled antibiotics and monoclonal antibodies. In this review, we summarize the current therapeutic options for the prevention and treatment of VAP, aiming to better management of VAP in clinical practice. |
| first_indexed | 2024-12-14T15:38:53Z |
| format | Article |
| id | doaj.art-44341da910fb4d7385acdebae60ab027 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T15:38:53Z |
| publishDate | 2019-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-44341da910fb4d7385acdebae60ab0272022-12-21T22:55:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-03-011010.3389/fphar.2019.00298432977Drug Prevention and Control of Ventilator-Associated PneumoniaXinming Xie0Jun Lyu1Tafseel Hussain2Manxiang Li3Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, ChinaClinical Research Center, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, ChinaVentilator-associated pneumonia (VAP) is one of the most prevalent and serious complications of mechanical ventilation, which is considered a common nosocomial infection in critically ill patients. There are some great options for the prevention of VAP: (i) minimize ventilator exposure; (ii) intensive oral care; (iii) aspiration of subglottic secretions; (iv) maintain optimal positioning and encourage mobility; and (v) prophylactic probiotics. Furthermore, clinical management of VAP depends on appropriate antimicrobial therapy, which needs to be selected based on individual patient factors, such as previous antibacterial therapy, history of hospitalization or mechanical ventilation, and bacterial pathogens and antibiotic resistance patterns. In fact, antibiotic resistance has exponentially increased over the last decade, and the isolation of a multidrug-resistant (MDR) pathogen has been identified as an independent predictor of inadequate initial antibiotic therapy and which is significantly associated with increased mortality. Multiple attempts were used in the treatment of VAP, such as novel antibacterial agents, inhaled antibiotics and monoclonal antibodies. In this review, we summarize the current therapeutic options for the prevention and treatment of VAP, aiming to better management of VAP in clinical practice.https://www.frontiersin.org/article/10.3389/fphar.2019.00298/fullantibioticsmonoclonal antibodiesprobioticschlorhexidineventilator-associated pneumonia |
| spellingShingle | Xinming Xie Jun Lyu Tafseel Hussain Manxiang Li Drug Prevention and Control of Ventilator-Associated Pneumonia Frontiers in Pharmacology antibiotics monoclonal antibodies probiotics chlorhexidine ventilator-associated pneumonia |
| title | Drug Prevention and Control of Ventilator-Associated Pneumonia |
| title_full | Drug Prevention and Control of Ventilator-Associated Pneumonia |
| title_fullStr | Drug Prevention and Control of Ventilator-Associated Pneumonia |
| title_full_unstemmed | Drug Prevention and Control of Ventilator-Associated Pneumonia |
| title_short | Drug Prevention and Control of Ventilator-Associated Pneumonia |
| title_sort | drug prevention and control of ventilator associated pneumonia |
| topic | antibiotics monoclonal antibodies probiotics chlorhexidine ventilator-associated pneumonia |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00298/full |
| work_keys_str_mv | AT xinmingxie drugpreventionandcontrolofventilatorassociatedpneumonia AT junlyu drugpreventionandcontrolofventilatorassociatedpneumonia AT tafseelhussain drugpreventionandcontrolofventilatorassociatedpneumonia AT manxiangli drugpreventionandcontrolofventilatorassociatedpneumonia |